Half Year Results 

Oxford Biomedica in good company

Oxford Biomedica in good company

Oxford Biomedica (OXB) was unable to match the Axovant and Sanofi (Bioverativ) licence income generated during the first half of 2018. The impact on the top line was mitigated to an extent by a 23 per cent increase in bioprocessing and commercial development revenues. But the relative shortfall was most noticeable in the cell therapy group’s net operating cash flow, which came in at £1.31m, against £18.3m in last year’s half-year results.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now